MaxCyte raises 2026 revenue floor to $34.5m and targets reagent maker Akron Bio

MaxCyte is proposing to move into the materials that cell therapy developers consume as well as the technology they use. On 10 November, alongside third-quarter results, the US company said it intends to acquire Akron Bio, which supplies GMP-grade reagents for cell therapy manufacturing. It plans to fund part of the purchase with a $22 million draw on its MidCap Financial credit facility. The deal is described as proposed, not completed. The price, expected closing date and conditions were not available in the material reviewed.

The results gave the announcement its backdrop. Revenue for the three months to 30 September was $10.2 million, which MaxCyte presented as 49% growth on the same period last year. Core revenue made up $8.2 million, and a further $2.0 million came from business linked to its SPL programmes. The company booked a net loss of $4.8 million and held $132.7 million in cash and investments at quarter-end.

MaxCyte also lifted its full-year revenue guidance to at least $34.5 million. The material reviewed does not state the earlier guidance or explain what drives the new figure, so the size of the upgrade cannot be judged. Nor is it clear whether Akron Bio would contribute to the outlook.

With no financial terms disclosed, it is too early to say how the acquisition would affect margins, leverage or the customer base. The same applies to reagent supply arrangements at Akron Bio's existing customers.